Peer-Reviewed Study Validates Reliability and Reproducibility of Esopredict, Previse’s Prognostic Assay for Patients with Barrett’s Esophagus

BALTIMORE, Sept. 11, 2024 /PRNewswire/ — Previse, a gastrointestinal health company, announced the publication of a study in Diagnostics highlighting the analytical validation of Esopredict, a first-in-class DNA methylation test for identifying patients with precancerous Barrett’s…